Pharmacists News

 
 
  • ESMO 2018'Outstanding' Ovarian Cancer PFS With Olaparib Maintenance Patients with newly diagnosed advanced ovarian cancer have a marked increase in progression-free survival with maintenance olaparib after successful first-line chemotherapy, phase 3 study data indicates.
  • ESMO 2018Palbociclib in Breast Cancer: New Overall Survival Data Final results from the PALOMA 3 study show that addition of palbociclib to fulvestrant improves overall survival by 7 months, but the result was not statistically significant. So now what?
  • ESMO 2018New Hope in Triple Negative Breast Cancer With Immunotherapy For the first time, a survival benefit with immunotherapy has been shown in breast cancer with atezolizumab plus chemotherapy in triple negative patients.
  • ESMO 2018Details of Study That Led to Radium-223 Restriction in Europe Details of the study that led to the restriction of the indication for the radiopharmaceutical radium-223 in prostate cancer have now been reported, and that restriction is questioned.
  • Trump's 'Public Charge' Plan 'Jeopardizes' Health, Groups Say One official said the plan goes after things "essential to human survival" and that advocates will sue to overturn the proposal if it is not withdrawn.
  • WSCEDAS Surgery Shows Promise for Intracranial Stenosis A phase 2a study provides preliminary evidence that EDAS surgery to reroute brain arteries, used to treat moyamoya disease, may also reduce recurrent stroke in patients with intracranial stenosis.
  • A Novel Treatment Approach for PML Progressive multifocal leukoencephalopathy, caused by the JC virus, has no known treatment. A new study offers a novel approach using T-cell infusions from the more treatable BK virus.
  • CHMP Backs Antiarrhythmic for Muscle-Contraction Disorders The EMA committee has recommended marketing authorization for the first treatment for adults with nondystrophic myotonia, a group of rare muscle contraction disorders characterized by pain and fatigue.
  • AAO 2018Drug Pipeline for Macular Degeneration in Focus at AAO Updates from phase 3 trials of VEGF inhibitors for neovascular age-related macular degeneration, and a novel genetic treatment, will be highlighted at the American Academy of Ophthalmology meeting.
  • ECNP 2018SSRIs a 'Double-Edged Sword' in Major Depression? SSRIs may amplify the living environment of patients with MDD so that those in more positive situations are more likely to remit compared with their counterparts living in less favorable conditions.
  • ESMO 2018Gender Differences in Chemo Side Effects Although outcomes and rates overall toxicity of esophagogastric cancer chemotherapy are similar for men and women, rates of nausea, diarrhea, and hair loss are higher in women, warn UK scientists.
  • ECTRIMS 2018Safe to Stop MS Disease-Modifying Therapy After Age 60? To add more evidence to the controversial debate over stopping immunomodulatory therapy for multiple sclerosis after age 60, researchers focus on quality of life, walking performance, and relapse rates.
  • PET Scans Show No Brain GABA Receptor Deficiency in Autism The potential therapeutic target of brain GABA type A deficiency linked to reduced receptors is undercut by an imaging study showing no reduction in receptors, although possible impairment in signaling.
  • FDA Panel Backs Prucalopride for Chronic Idiopathic Constipation An FDA panel unanimously recommended prucalopride oral tablets for the treatment of adults with chronic idiopathic constipation.
  • More Than Half of Physicians and Nurses Say Obesity Is a Disease A Medscape poll found physicians were more likely than nurses to say that lifestyle was the underlying cause of obesity. Diet change was the top recommendation all providers gave to patients who were obese.
  • Plans for Canakinumab CV Indication Hit Roadblock With FDA The anti-inflammatory drug made a big splash in the CANTOS trial, but the agency is calling for more data on responders.
  • 'Major Breakthrough' in Cystic Fibrosis Treatment Adding a third drug to modulate the CFTR protein improved respiratory function and reduced sweat chloride concentrations in most patients with cystic fibrosis. Phase 3 trials are ongoing.
  • ECTRIMS 2018Novel Anti-B-Cell Therapy Looks Promising in MS A new and novel oral therapy for multiple sclerosis, which inactivates rather than depletes B cells, has shown promising results in its first efficacy study.
  • No Chemo; Rituximab Alone for Indolent Lymphoma? New results showing a 10-year overall survival rate of 73% with rituximab alone suggest that patients can skip chemotherapy. But this may not be appropriate for all patients, suggests an expert.
  • Immunotherapy Combos: Will Cost Put Them out of Reach? Immunotherapy has already revolutionized cancer care. Combining various immunotherapies promises even greater success, but will the already high cost of these therapies put combos out of reach?